Journal of Epidemiology
Online ISSN : 1349-9092
Print ISSN : 0917-5040
ISSN-L : 0917-5040
Original Articles
Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project
Shigekazu UkawaKoshi NakamuraEmiko OkadaMakoto HirataAkiko NagaiZentaro YamagataKaori MutoKoichi MatsudaToshiharu NinomiyaYutaka KiyoharaYoichiro KamataniMichiaki KuboYusuke NakamuraBioBank Japan Cooperative Hospital GroupAkiko Tamakoshi
Author information
JOURNAL FREE ACCESS

2017 Volume 27 Issue Supplement_III Pages S65-S70

Details
Abstract

Background: Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project.

Methods: Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated.

Results: Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing.

Conclusions: We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput “omics” technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.

Content from these authors

This article cannot obtain the latest cited-by information.

© 2017 The authors. This is an open access article under the CC BY-NC-ND license.
Previous article Next article
feedback
Top